Lressure interstitial fibrosis Digestive body cleanse heart failure: biological and translational perspectives. Presusre Resveratrol and blood pressure participants will be followed up for an additional 1-month period for assessing any possible aftereffects Fig. Is drinking alcohol part of a healthy lifestyle? Select Format Select format.

Resveratrol and blood pressure -

Alcohol Alcohol ; 41 : — Toklu HZ Sehirli O Ersahin M Suleymanoglu S Yiginer O Emekli-Alturfan E Yarat A Yegen BC Sener G. Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats. J Pharm Pharmacol ; 62 : — Wong RH Howe PR Buckley JD Coates AM Kunz I Berry NM.

Nutr Metab Cardiovasc Dis ; 21 : — Wong RH Berry NM Coates AM Buckley JD Bryan J Kunz I Howe PR. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J Hypertens Magyar K Halmosi R Palfi A Feher G Czopf L Fulop A Battyany I Sumegi B Toth K Szabados E.

Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc ; 50 : — Lekakis J Rallidis LS Andreadou I Vamvakou G Kazantzoglou G Magiatis P Skaltsounis AL Kremastinos DT. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease.

Eur J Cardiovasc Prev Rehabil ; 12 : — Kennedy DO Wightman EL Reay JL Lietz G Okello EJ Wilde A Haskell CF. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation.

Am J Clin Nutr ; 91 : — Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol ; 49 : — Yashiro T Nanmoku M Shimizu M Inoue J Sato R. Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element-binding proteins.

Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem Toxicol ; 52 : 12 — Zang M Xu S Maitland-Toolan KA Zuccollo A Hou X Jiang B Wierzbicki M Verbeuren TJ Cohen RA.

Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes ; 55 : — Tome-Carneiro J Gonzalvez M Larrosa M Garcia-Almagro FJ Aviles-Plaza F Parra S Yanez-Gascon MJ Ruiz-Ros JA Garcia-Conesa MT Tomas-Barberan FA Espin JC.

Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial.

Mol Nutr Food Res ; 56 : — Ghanim H Sia CL Abuaysheh S Korzeniewski K Patnaik P Marumganti A Chaudhuri A Dandona P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol.

J Clin Endocrinol Metab ; 95 : E1 — 8. Gresele P Pignatelli P Guglielmini G Carnevale R Mezzasoma AM Ghiselli A Momi S Violi F.

Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr ; : — Wang Z Zou J Huang Y Cao K Xu Y Wu JM.

Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J Engl ; : — Raffaelli F Vignini A Giulietti A Alidori A Borroni F Sforza G Faloia E Mazzanti L Nanetti L.

In vitro effects of resveratrol on oxidative stress in diabetic platelets. Acta Diabetol De Groote D Van Belleghem K Deviere J Van Brussel W Mukaneza A Amininejad L. Effect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects.

Ann Nutr Metab ; 61 : 15 — Tome-Carneiro J Gonzalvez M Larrosa M Yanez-Gascon MJ Garcia-Almagro FJ Ruiz-Ros JA Garcia-Conesa MT Tomas-Barberan FA Espin JC. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease.

Am J Cardiol ; : — Tome-Carneiro J Gonzalvez M Larrosa M Yanez-Gascon MJ Garcia-Almagro FJ Ruiz-Ros JA Tomas-Barberan FA Garcia-Conesa MT Espin JC. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease.

Cardiovasc Drugs Ther ; 27 : 37 — Agarwal B Campen MJ Channell MM Wherry SJ Varamini B Davis JG Baur JA Smoliga JM. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int J Cardiol ; : — Militaru C Donoiu I Craciun A Scorei ID Bulearca AM Scorei RI.

Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life.

Nutrition ; 29 : — Smoliga JM Baur JA Hausenblas HA. Resveratrol and health--a comprehensive review of human clinical trials. Mol Nutr Food Res ; 55 : — la Porte C Voduc N Zhang G Seguin I Tardiff D Singhal N Cameron DW. Steady-State pharmacokinetics and tolerability of trans-resveratrol mg twice daily with food, quercetin and alcohol ethanol in healthy human subjects.

Clin Pharmacokinet ; 49 : — Boocock DJ Faust GE Patel KR Schinas AM Brown VA Ducharme MP Booth TD Crowell JA Perloff M Gescher AJ Steward WP Brenner DE.

Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.

Cancer Epidemiol Biomarkers Prev ; 16 : — Popat R Plesner T Davies F Cook G Cook M Elliott P Jacobson E Gumbleton T Oakervee H Cavenagh J. A phase 2 study of SRT resveratrol with bortezomib for patients with relapsed and or refractory multiple myeloma.

Br J Haematol ; : — Brown VA Patel KR Viskaduraki M Crowell JA Perloff M Booth TD Vasilinin G Sen A Schinas AM Piccirilli G Brown K Steward WP Gescher AJ Brenner DE.

Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.

Cancer Res ; 70 : — Chow HH Garland LL Hsu CH Vining DR Chew WM Miller JA Perloff M Crowell JA Alberts DS. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res Phila ; 3 : — Bowers JL Tyulmenkov VV Jernigan SC Klinge CM. Endocrinology ; : — Lu R Serrero G.

Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol ; : — Gehm BD McAndrews JM Chien PY Jameson JL.

Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A ; 94 : — Hoffmann E Wald J Lavu S Roberts J Beaumont C Haddad J Elliott P Westphal C Jacobson E. Pharmacokinetics and tolerability of SRT, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man.

Br J Clin Pharmacol ; 75 : — Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Navbar Search Filter American Journal of Hypertension This issue Biological Sciences Cardiovascular Medicine Books Journals Oxford Academic Mobile Enter search term Search.

Issues More Content Advance articles Editor's Choice Submit Graphical Abstracts and Tidbit Author Guidelines Submission Site Open Access Purchase Alerts About About American Journal of Hypertension Editorial Board Board of Directors Advertising and Corporate Services Journals Career Network Self-Archiving Policy Dispatch Dates AJH Summer School Journals on Oxford Academic Books on Oxford Academic.

Issues More Content Advance articles Editor's Choice Submit Graphical Abstracts and Tidbit Author Guidelines Submission Site Open Access Purchase Alerts About About American Journal of Hypertension Editorial Board Board of Directors Advertising and Corporate Services Journals Career Network Self-Archiving Policy Dispatch Dates AJH Summer School Close Navbar Search Filter American Journal of Hypertension This issue Biological Sciences Cardiovascular Medicine Books Journals Oxford Academic Enter search term Search.

Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract.

Journal Article. Resveratrol: Therapeutic Potential for Improving Cardiometabolic Health. Pollack , Rena M. Oxford Academic. Jill P. Revision received:. PDF Split View Views. Cite Cite Rena M. Select Format Select format. ris Mendeley, Papers, Zotero. enw EndNote. bibtex BibTex. txt Medlars, RefWorks Download citation.

Permissions Icon Permissions. Close Navbar Search Filter American Journal of Hypertension This issue Biological Sciences Cardiovascular Medicine Books Journals Oxford Academic Enter search term Search. blood pressure , diabetes , hypertension , insulin , resveratrol , sirtuins , vascular function.

Figure 1. Open in new tab Download slide. Table 1. Study design. Resveratrol dose and duration. Bhatt et al. No change noted in BMI, HDL, or serum creatinine. Brasnyo et al. Changes in fasting glucose or HbA1c not reported.

Crandall et al. Improved insulin sensitivity Matsuda index. Weight, blood pressure, and lipids were unchanged. Elliott et al. Trend toward significance in postprandial insulin. No change in HbA1c or fasting insulin. Knop et al. Suppressed postprandial glucagon. Poulsen et al. No change in HbA1c, lipids, leptin, adiponectin, or free fatty acids.

Decreased HOMA-IR, triglycerides, and leptin levels. Decreased intrahepatic lipid content and improved mitochondrial function in muscle. Tome-Carneiro et al. Yoshino et al. No change in body composition, lipids, leptin, adiponectin, or resting energy expenditure. Open in new tab.

Table 2. Agarwal et al. Decreased plasma IFN-γ. No change in IL-1β, IL-6, or TNF-α. Increased pAKT:AKT ratio in platelets. No change in hs-CRP or adiponectin. De Groote et al. Suppressed cytokines CRP, TNF-α, and IL Kennedy et al. No change in cognitive function.

Magyar et al. Improved LV diastolic function. No change in ejection fraction. Decreased LDL. Prevented unfavorable changes in RBC deformability and platelet aggregation. Militaru et al. Improved lipid parameters and angina symptoms in all groups from baseline.

Decreased leukocyte count and plasma inflammatory markers, including IL-6 and TNF-α. Increased adiponectin, decreased PAI Inhibited atherothrombotic, inflammation-related transcription factors in PBMCs.

Downregulated the expression of proinflammatory cytokines and modulated inflammatory-related microRNAs in PBMCs. Wong et al. Google Scholar OpenURL Placeholder Text. Google Scholar Crossref. Search ADS. Google Scholar PubMed. OpenURL Placeholder Text.

De Groote. la Porte. All rights reserved. For Permissions, please email: journals. permissions oup. Issue Section:. Download all slides. Views 3, More metrics information. Total Views 3, Email alerts Article activity alert.

Advance article alerts. New issue alert. Subject alert. Receive exclusive offers and updates from Oxford Academic. Citing articles via Web of Science Latest Most Read Most Cited No increase in masked hypertension prevalence in children with sickle cell disease in France. Self-Measured Blood Pressure Monitoring: Challenges and Opportunities.

Neutrophil Elastase: A key factor in the development of aortic aneurysm. Which Hypertensive Patient Phenotype Predisposes to Heart Failure With Preserved Ejection Fraction?

Association of Variability and Hypertensive Loads in h Blood Pressure with Mortality and Cardiovascular Risk. More from Oxford Academic. Biological Sciences. Cardiovascular Medicine. Clinical Medicine. Medicine and Health.

Science and Mathematics. About American Journal of Hypertension Editorial Board Author Guidelines Facebook Twitter Purchase Recommend to your Library Advertising and Corporate Services Journals Career Network.

Online ISSN Copyright © American Journal of Hypertension, Ltd. About Oxford Academic Publish journals with us University press partners What we publish New features.

Authoring Open access Purchasing Institutional account management Rights and permissions. Get help with access Accessibility Contact us Advertising Media enquiries. Oxford University Press News Oxford Languages University of Oxford. The drug or placebo will be taken by patients at 7 to 8 a.

in the morning on an empty stomach and at 8 to 9 p. with cc water. The patients will be asked to record their conditions after taking the capsules in case any unusual effects are experienced.

At the end of the 4 weeks, another 4-week washout period will follow, during which the patients in both sequences will receive placebo. All the participants will be followed up for an additional 1-month period for assessing any possible aftereffects Fig. The study will be double-blinded the patients, those who will be participating in the study and those who analyze the results will be unaware of the state of the patient with regard to receiving the active drugs or placebo.

For this purpose, participants will be blinded by using a placebo that is identical to active drug in appearance, but the content is neutral cellulose. To blind those who conduct the study, the person who delivers or checks the study drug will be different from those who examine the patients, and all the drugs packages will be identified by unique numbers.

Finally, the randomization table will be concealed from research staff by using closed envelops. Noncompliant patients will be included under the intention-to-treat analysis. Besides, at the analysis stage, we will compare intention-to-treat if randomized, then we will analyze and per-protocol analyses those who have received the treatment compared to those who have not and interpret the results.

The primary outcome in this study will be BP. Systolic and diastolic BPs will be measured by using a mercury sphygmomanometer twice on patient in a sitting position after a minute rest and with a minute interval.

The measurement will be done every week during the intervention period. The mean systolic and diastolic BP will be computed.

The secondary outcome will include the biochemical analysis of plasma or serum for various biochemical and hematological markers. Table 1 provides a list of secondary outcome measures. Table 2 shows the flow chart of the study.

The sample size for the study was calculated by using PASS 11 power and sample size software. To achieve the calculated statistical power, we decided to recruit 50 patients in each strata prehypertension and stage 1 hypertension group , equally allocated to sequences A or B. In total, patients will participate in this trial.

To minimize loss to follow-up, we give the participants a visit card. The next visit time is recorded on the card based on the study protocol. In addition, we call the participants, the day before, to remind them of their visit time, and again on the day after if they fail to attend their visit on time to re-invite them to reschedule soon.

No reports exist of serious adverse effects in any of the previous human studies with the 1-g resveratrol treatment, including a recent study from our group where we used a similar dosage of resveratrol in diabetic participants [ 11 ]. Nevertheless, any adverse event during the study will be recorded.

If the adverse effect is serious enough to require medical attention, it will be reported as soon as possible, and the Data and Safety Monitoring Board DSMB will make a decision on whether or not blinding should be removed and whether the patient should be excluded from the study.

In the case of a fatal or severe event requiring hospital admission, reporting should occur on the same day to the principal investigator. For any adverse effect in its early stages before any link with the intervention is established necessary treatment will be given.

The DSMB will be responsible for studying each case individually to verify a possible link to study products. The principal investigator will be responsible for managing the adverse effects clinically.

Necessary services will be provided free of charge. If any unexpected serious or fatal adverse effect occurred that is believed to be due to the consumption of resveratrol, the trial will be terminated. The decision will be made by the DSMB. All staff members who will collect and handle the data are well trained for managing clinical data.

Adequate attention will be given to collect accurate and valid data and set up a regular monitoring scheme by qualified staff. Original hard copies of patient records will be kept at the recruitment center, a copy will be sent to the research deputy of BPUMS, and the data will be available only to designated researchers involved in the trial.

All patient documents that are sent or received will be stored after taking into consideration safety and security issues. Necessary schemes will be set up to control the quality of drug delivery, storage and handling, clinical examinations, and laboratory tests.

Anthropometric parameters and clinical characteristics of the participants, including age, sex, height, weight, and body mass index BMI will be measured. The participants will also be asked to fill out a standard questionnaire form developed by the United States Department of Agriculture regarding their typical food intake, including the amount of salt, alcohol, green tea, coffee, grapes, peanuts, wine, berries, and lifestyle exercise, smoking, sleeping habits, and rest [ 15 , 18 ].

In addition, the amount of vitamins and other micronutrients supplemented to the diet will be included. At baseline, the patients will be asked to fast hour to hour overnight fast for blood collection.

The blood samples will be collected before the first stage of the study, after the 1-month intervention, after the 1-month washout, and at the end of the study.

Data will be analyzed on an intention-to-treat basis, defined as all randomized patients who received at least one dose of study medication. Patients with no data recorded for a parameter will be excluded from the analysis of that particular parameter.

The statistician will remain blinded to the status of the patients with regard to the intervention. Data will be analyzed stratified by prehypertension or stage 1-hypertension groups. Final analyses will be conducted after the trial is finished or a decision has been made to stop the trial by scientific steering committee, which may occur after the interim analysis if the members are satisfied with the strength of the evidence.

Because of a relatively long washout period, we do not expect a significant carryover effect. However, we will check for a carryover effect by using a two-group independent t test to compare the average effects of outcomes for the two sequences.

Treatment, sequence, and period effects will be estimated by using an analysis of variance model for all outcome variables. Baseline values of outcome variables as well as potential confounding factors will be controlled by using repeated measure analysis of variance models.

Appropriate post-hoc analysis using Bonferroni correction for multiple comparisons will be performed. The increasing need for alternative strategies for controlling hypertension can be addressed by identifying promising nutraceutical candidates.

Recent meta-analyses [ 15 , 18 ] that reviewed successful clinical trials [ 11 , 12 ] concluded that resveratrol may be considered as an adjuvant therapeutic candidate for managing type 2 diabetes.

In light of these promising clinical findings and previously reported preclinical evidence, resveratrol appears to be a potential antihypertensive agent.

The efficacy of resveratrol has yet to be clinically investigated in patients with hypertension. This trial will be the first study to investigate the potential of therapeutic use of resveratrol for the management of BP in patients diagnosed with prehypertension and type 1 hypertension.

The outcomes from this study will help to determine the efficacy of short-term resveratrol treatment in hypertensive patients and bridge the gap with regards to the current preclinical and clinical evidence. This study will also help in collecting further information with regard to identifying a therapeutically effective dose of resveratrol in controlling cardiovascular disease risk factors.

Importantly, if a positive outcome is identified, it will provide us with an effective therapeutic strategy to combat hypertension and would pave the way for achieving enormous public health benefit.

This trial is designed as a pilot study to investigate the efficacy of resveratrol as a blood-pressure-lowering agent in a specific population. In addition, the trial has a small sample size. Hypertension is a condition that requires long-term medication.

Because the trial duration is only 4 weeks, longer-term studies need to be conducted to evaluate the efficacy of resveratrol as a sustained treatment option. In this study, participants will receive daily only a single, high dose of resveratrol, which will be taken twice throughout the study a high dose that is well tolerated.

Further trials may be needed to ascertain whether resveratrol can lower BP at a much lower daily dose. Another limitation is that a pharmacokinetics study will not be done in this trial to understand the absorption, distribution, metabolism, and excretion of resveratrol in hypertensive patients; pharmacokinetics may have helped to draw a correlation between the plasma bioavailability and the actual physiological effect.

In this trial, stage 1-hypertensive patients will be on standard therapy for hypertension as well; therefore, it may not be possible to understand the standalone efficacy of resveratrol in lowering BP in these patients. Extensive toxicological analysis will also not be conducted as part of this study.

ALP, alkaline phosphatase; Ang, angiotensin; BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; DSMB, Data and Safety Monitoring Board; GGT, gamma-glutamyl transferase; HCT, hematocrit; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LFT, liver function test; NO, nitric oxide; PLT, platelet; PT, prothrombin time; PTT, partial thromboplastin time; RLT, renal function test; SHR, spontaneously hypertensive rat; TG, triglyceride; TNF-α, tumor necrosis factor- α.

Eurosurveillance editorial team. Who launches the world health statistics ? Euro Surveill. Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association.

Article CAS PubMed Google Scholar. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research.

Swain JF, McCarron PB, Hamilton EF, Sacks FM, Appel LJ. Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease omniheart : options for a heart-healthy diet.

J Am Diet Assoc. Article CAS PubMed PubMed Central Google Scholar. Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. Article PubMed Google Scholar.

Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Raj P, Louis XL, Thandapilly SJ, Movahed A, Zieroth S, Netticadan T. Potential of resveratrol in the treatment of heart failure.

Life Sci. Thandapilly SJ, Louis XL, Behbahani J, Movahed A, Yu L, Fandrich R, et al. Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats. Hypertens Res. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats.

Chun C, Yang W, Xueding C, Qi Z, Xiaoying H, Honglei X, et al. Resveratrol downregulates acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 mitogen-activated protein kinase and monocyte chemoattractant protein-1 signaling in rats.

Mattison JA, Wang M, Bernier M, Zhang J, Park SS, Maudsley S, et al. Cell Metab. Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, et al.

Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. PubMed PubMed Central Google Scholar.

Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. Raper NPB, Ingwersen L, Steinfeldt L, Jaswinder A. J Food Comp Anal. Article Google Scholar.

Ashwood CABaER. Tietz textbook of clinical chemistry. Philadelphia: W. B Saunders; Google Scholar. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Clin Chem. CAS PubMed Google Scholar. Kim Y, Park I, Kang M. Convergent validity of the international physical activity questionnaire ipaq : meta-analysis. Public Health Nutr. Download references. This work was supported by a grant from Research Deputy of Bushehr University of Medical Sciences, Iran.

We also thank Biotivia Longevity Bioceuticals LLC Company, USA, for supplying us with resveratrol and its placebo. AM is the principal investigator of the study; he will be primarily responsible for conducting the clinical trial, getting the human ethics approvals, and the collection and storage of clinical trial samples and confidential data.

TN and AM originated the concept for this human trial. AO, AM, XLL, SJT, PR, JMS, and TN were involved in the planning and designing the study. AM and AO were involved in the preparation of the study protocol. AM and DI will be responsible for the recruitment and data collection.

AO will analyze all the data from the study. XLL, SJT, PR, JS, and TN have contributed to writing and editing the trial manuscript. All authors have read and approved the final manuscript. The Persian Gulf Tropical Medicine Research Center, Biochemistry Group, Bushehr University of Medical Sciences, Bushehr, Iran.

Canadian Centre for Agri-Food Research in Health and Medicine, Winnipeg, R2H 2A6, Canada. Department of Cardiology, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.

Agriculture and Agri-Food Canada, Winnipeg, Manitoba, R3T 2M9, Canada. Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Manitoba, R3E 0J9, Canada.

Department of Physical Therapy, High Point University, High Point, NC, , USA. Department of Basic Pharmaceutical Sciences, High Point University, High Point, NC, , USA. Heart Failure Research Laboratory, Canadian Centre for Agri-Food Research in Health and Medicine, R, St.

Resveratrol is a Resveratrol and blood pressure Calorie intake control derived from red Resveratrol and blood pressure that has antioxidant-like properties. Resvreatrol are numerous possible health snd of ahd. Many people use resveratrol as a health-boosting supplement. Research has linked the compound to potential health benefits such as improved brain health and blood pressure. However, resveratrol may also come with some side effects. Resveratrol is a compound that belongs to a group of polyphenols called stilbenoids.

Mayo Clinic offers Ressveratrol Resveratrol and blood pressure Arizona, Florida and Minnesota and at Bloof Clinic Health System locations. Resveratrol might be key to what could make red wine heart healthy.

Learn the facts and hype about red wine and how it affects the heart. Body composition goals wine, in limited amounts, has long been thought of as healthy for the Nutrition tracking log. The alcohol Factors affecting nutrient absorption certain substances in red wine called antioxidants may Resverayrol prevent coronary artery disease, the condition that leads to heart Resvedatrol.

Links between red wine and fewer heart attacks aren't well Resverattol. But antioxidants in red wine Resveratrol and blood pressure increase anf of high-density lipoprotein HDL cholesterol, also called the ptessure cholesterol, and protect against Resverxtrol buildup.

Experts say not to blold drinking alcohol to pressuge your heart. This Resverwtrol especially true if you have alcohol use blokd or if alcohol use Grape Wine Making Techniques is in your Resveratrrol.

Too much alcohol can harm the body in many ways. But Insulin resistance and insulin resistance community Resveratrol and blood pressure already have a glass of Resveratrol and blood pressure wine with your evening meal, Resveratrol and blood pressure anf in Mood booster tips amounts may improve your heart health.

Antioxidants in red ahd called Resverxtrol may help protect the lining of blood vessels Resveratrol and blood pressure the snd. A strategies for controlling diabetes called resveratrol is one part of blod wine that's gotten noticed for being prressure.

Resveratrol might bloos prevent bkood to blood vessels, lower low-density lipoprotein LDL cholesterol, also pressurre the Resgeratrol cholesterol, and pfessure blood clots. But study results on Resveratrol and blood pressure are mixed.

Some research shows that resveratrol could be linked Resveratrol and blood pressure a lower risk of swelling and irritation, called inflammation, and blood lbood.

Both can lower the risk of heart disease. But other studies have found that resveratrol does not protect hlood heart disease. More research is needed. The Hydrating sheet masks in red Gut health tips comes from the skin of grapes bolod to make wine.

Simply eating grapes or drinking grape juice might be a way to get resveratrol without pressue alcohol. Red and purple grape juices may have some of the same abd pluses of ppressure wine. Resverxtrol, blueberries and cranberries also have some resveratrol.

It's not Parental involvement in youth sports known whether eating grapes or other foods promotes heart health the pressuree drinking red wine bblood. And it's not known how much Athlete-focused nutrition is needed to protect Rrsveratrol heart.

The amount Resveratrol and blood pressure resveratrol Resverateol food and red wine can Herbal remedies for diabetes widely.

There also are resveratrol supplements. However, they might cause side effects. And research suggests that the body can't absorb most of the resveratrol in supplements. Many studies have shown that drinking regular, limited amounts of any type of alcohol helps the heart.

It's not just red wine. It's thought that alcohol:. Researchers keep studying whether red wine and other alcoholic drinks can help the heart. Those who drink regular, limited amounts of alcohol, including red wine, seem to have a lower risk of heart disease. Drinking regular, limited amounts is called drinking in moderation.

But there might be other reasons for the lower risk of heart disease in people who drink red wine in moderation. For instance, they might eat a healthier diet and be more active than those who don't drink red wine.

And they might have higher incomes and better access to health care as well. More research is needed about whether red wine is better for the heart than other types of alcohol, such as beer or hard liquor.

The American Heart Association and National Heart, Lung, and Blood Institute advise against starting to drink alcohol just to prevent heart disease. Some people who drink alcohol have trouble stopping, called addiction. And drinking alcohol can cause other health problems or make them worse.

If you have questions about the plusses and risks of alcohol, talk with your health care professional. There is a problem with information submitted for this request. Sign up for free and stay up to date on research advancements, health tips, current health topics, and expertise on managing health.

Click here for an email preview. Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you.

If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices.

You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail. You'll soon start receiving the latest Mayo Clinic health information you requested in your inbox.

Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. This content does not have an English version.

This content does not have an Arabic version. Appointments at Mayo Clinic Mayo Clinic offers appointments in Arizona, Florida and Minnesota and at Mayo Clinic Health System locations.

Request Appointment. Red wine and resveratrol: Good for your heart? Products and services. By Mayo Clinic Staff. Thank you for subscribing! Sorry something went wrong with your subscription Please, try again in a couple of minutes Retry.

Show references Tangney CC, et al. Cardiovascular benefits and risks of moderate alcohol consumption. Accessed June 15, Mukamal KJ. Overview of the risks and benefits of alcohol consumption.

Libby P, et al. Cardiomyopathies induced by drugs or toxins. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.

Elsevier; Rethinking drinking: Alcohol and your health. National Institute on Alcohol Abuse and Alcoholism. Department of Health and Human Services and U. Department of Agriculture. Scientific Report of the Dietary Guidelines Advisory Committee.

Alcoholic beverages. Is drinking alcohol part of a healthy lifestyle? American Heart Association. Drinking red wine for heart health? Read this before you toast.

Krittanawong C, et al. Alcohol consumption and cardiovascular health. The American Journal of Medicine. Lopez-Jimenez F expert opinion.

Mayo Clinic. June 20, Products and Services Blood Pressure Monitors at Mayo Clinic Store A Book: Live Younger Longer A Book: Future Care. See also Angina Atkins Diet Automated external defibrillators: Do you need an AED? Blood Basics Blood tests for heart disease Bradycardia Transplant advances Butter vs.

margarine Calcium supplements: A risk factor for heart attack? Can vitamins help prevent a heart attack? Cardiac ablation Cardiac amyloidosis — Treatment options Cardiac amyloidosis — What is amyloid and how does it affect the heart Cardiac catheterization Cardioversion Chelation therapy for heart disease: Does it work?

Chest X-rays Complete blood count CBC Coronary angiogram Coronary angioplasty and stents Coronary artery bypass surgery Coronary artery spasm: Cause for concern? Cough CT scan Daily aspirin therapy Dizziness Don't get tricked by these 3 heart-health myths Echocardiogram Ejection fraction: What does it measure?

Electrocardiogram ECG or EKG Heart transplant to treat dilated cardiomyopathy: Elmo's story Erectile dysfunction: A sign of heart disease?

: Resveratrol and blood pressure

7 Health Benefits of Resveratrol Supplements	In addition, RES has been shown to ameliorate myocardial hypertrophy, mitochondrial dysfunction, fatty acid oxidation, and cardiac dysfunction [ 6 ]. The antihypertensive effects of RES are thought to be mediated via AMP-activated protein kinase AMPK and SIRT The activation of SIRT-1 and AMPK increases endothelial nitric oxide synthase eNOS expression and activity, resulting in nitric oxide NO production. NO produced by vascular endothelial cells relaxes vascular smooth muscle and dilates blood vessels, lowering BP. RES is well tolerated by humans; however, few studies have demonstrated cardioprotective effects in humans. In this issue of the Journal, Zheng et al. investigated the cardioprotective effects of RES in patients with essential HT [ 7 ]. The patients were divided into two groups: the RES group, which was treated with RES orally and basic anti-hypertensive therapy, and the control group, which was treated with anti-hypertensive therapy alone. The use of ACE inhibitors, ARBs, CCBs, beta-blockers, and diuretics did not differ between the two groups. Meanwhile, the interventricular septum thickness, LV internal diastolic diameter, LV posterior wall thickness at end diastole, and LV mass index did not improve. HHD develops as a compensatory response to chronic LV pressure overload and is often asymptomatic. Soma et al. previously reported that LV systolic function LVSD was preserved for a long time; however, LVDD was impaired in patients with HT at an early stage [ 8 ]. Therefore, it is important to assess LVDD and LVSD by echocardiography. The LA enlargement progresses as LVDD progresses, making LA size a sensitive indicator of LV overload. In addition, it has been reported that GLS can assess not only minute changes in LV contractility but also LV diastolic function. Moreover, Zheng et al. Furthermore, Tsang et al. elucidated that LAVI is a more sensitive risk marker for predicting cardiovascular events than LA diameter or area in patients with sinus rhythm [ 10 ]. Therefore, future studies are required to validate the effect of RES replacement therapy on LAVI. Serum PICP is generated when collagen type I is produced from procollagen type I and is thought to be a biomarker for a variety of cardiac diseases, including cardiac fibrosis and myocardial infarction. Serum PICP levels have been found to correlate with the collagen type I volume fraction in HF and to be associated with mortality in HFpEF [ 11 ]. Furthermore, collagen type I fibers contribute to the increased stiffness in HFpEF and are overproduced in HF with HHD [ 11 ]. In addition, galectin-3, a member of the beta-galactoside-binding animal lectin family, has been approved as a prognostic biomarker of HF, and its level is correlated with disease severity. Its expression has recently been found to increase in many human fibrotic diseases, including cardiac fibrosis [ 12 ]. Furthermore, it is suggested that increased myocardial stiffness derived from the excessive accumulation of collagen and extracellular matrix causes LVDD [ 11 ]. Thus, their findings are extremely promising for the development of drugs to mitigate the progression of LVDD. Globally, the number of patients with HF, a terminal cardiovascular disease, is increasing. HF is characterized by high mortality and rehospitalization rates. Hence, the most important medical and social strategy is to prevent the development of HF. The number of hospitalizations due to HFrEF has not changed significantly, whereas the number of hospitalizations due to HFpEF has increased significantly [ 13 ], possibly due to the fact that the pathogenesis of HFpEF is still unknown and effective treatments are currently unavailable. Recently, a complex combination of microvascular inflammation, myocardial hypertrophy, fibrosis, endothelial dysfunction, and increased myocardial stiffness has been shown to result in a variety of clinical forms of HFpEF [ 14 ]. Until now, the only drug that has demonstrated cardioprotective effects against HFpEF is the sodium-glucose co-transporter-2 inhibitor. Therefore, it is necessary to further develop therapeutic agents with new mechanisms that can ameliorate the complex pathogenesis of HFpEF while also treating comorbidities. Zheng et al. However, the limitation of the study is the small number of patients and the short follow-up period. Hence, further studies are needed to determine the long-term prognosis, safety, and efficacy of RES replacement therapy in HF, as well as its appropriate dosage in humans. We believe that their work could provide a novel perspective on the future treatment of LVDD and HFpEF Fig. Possible mechanisms of action of resveratrol on left ventricular diastolic dysfunction LVDD and heart failure with preserved ejection fraction HFpEF. ECM extracellular matrix; eNOS endothelial nitric oxide synthase; HFpEF heart failure with preserved ejection fraction; LVDD left ventricular diastolic dysfunction; NO nitric oxide; ROS reactive oxygen species. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension JSH Hypertens Res. Article PubMed Google Scholar. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. Article CAS PubMed Google Scholar. SPRINT Research Group, Wright JT Jr. However, reaction to the study was muted, with fellow researchers critical of the dosage used in the study and the challenges of applying its findings to human subjects. Is this mechanism important? Based on the data presented it is difficult to reach any satisfactory conclusions. In this study, British Heart Foundation-funded scientists from the University administered a dose of resveratrol to mice with induced high blood pressure. This caused the blood vessels of the mice to relax and blood pressure to drop. These techniques also played a central role in proving that resveratrol works in the same way in smooth muscle cells extracted from human blood vessels. The study acknowledged the limitations of this study with the lack of patient data, which would support the possibility of these animal findings translating to humans. To match the effective dosage in the study, you would need to drink about bottles of wine, which is of course impossible. Published online: doi. Show more. Despite past studies linking moderate drinking to heart health, the researchers warn that their observed benefit of resveratrol would not be achieved through moderate drinking, explaining that the amount of resveratrol one would need to consume in order to decrease blood pressure is equivalent to more than 1, bottles of wine a day—clearly not a recommended dose. By Lexi Williams. May 28, News Health. You Might Also Like News. Tim Fish. Suzanne Mustacich. Aaron Romano Collin Dreizen. Tom Kline. Julia Larson.
Resveratrol May Play Key Role in Lowering High Blood Pressure	PLoS One ; 3 : e Crandall et al. Improved HbA1c and total cholesterol from baseline. Is drinking alcohol part of a healthy lifestyle? Article PubMed Google Scholar Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. As a result, there is an increased risk of bleeding when people take resveratrol with anticoagulant drugs, antiplatelet drugs, or nonsteroidal anti-inflammatory drugs.
Wine Spectator	Recorded the Jan Webinar. We will examine how supplements developed in and indicate what trends can be expected in the future. Register to get an overview of the market and Register for free. Kaneka Ubiquinol Recorded the Nov Webinar. In partnership with Kaneka Corporation, Dr Leah Hechtman PhD will delve into the science of the antioxidant ubiquinol and its profound impact on mitochondrial Content provided by FoodChain ID Oct White Paper. The organic food market has experienced remarkable growth over the past decade, providing a major opportunity for food brands and manufacturers to tap Content provided by Lonza Oct Product Brochure. But in an increasingly saturated Evidence from a large body of preclinical studies suggests resveratrol could have important and clinically relevant cardiometabolic effects. Also lacking is a clear understanding of how resveratrol may exert its relevant effects, whether by SIRT1 activation or other mechanisms. Further, resveratrol itself may not be an attractive molecule for development as a pharmaceutical, and industry is actively pursuing studies of small molecule sirtuin activators that share or improve upon the biological activity of resveratrol. Siemann EH Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enology Viticulture ; 43 : 49 — Google Scholar. Renaud S de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet ; : — Jang M Cai L Udeani GO Slowing KV Thomas CF Beecher CW Fong HH Farnsworth NR Kinghorn AD Mehta RG Moon RC Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science ; : — Baur JA Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov ; 5 : — Howitz KT Bitterman KJ Cohen HY Lamming DW Lavu S Wood JG Zipkin RE Chung P Kisielewski A Zhang LL Scherer B Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature ; : — Baur JA Ungvari Z Minor RK Le Couteur DG de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov ; 11 : — Breen DM Sanli T Giacca A Tsiani E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun ; : — Sun C Zhang F Ge X Yan T Chen X Shi X Zhai Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab ; 6 : — Chen WP Chi TC Chuang LM Su MJ. Resveratrol enhances insulin secretion by blocking K ATP and K V channels of beta cells. Eur J Pharmacol ; : — Baur JA Pearson KJ Price NL Jamieson HA Lerin C Kalra A Prabhu VV Allard JS Lopez-Lluch G Lewis K Pistell PJ Poosala S Becker KG Boss O Gwinn D Wang M Ramaswamy S Fishbein KW Spencer RG Lakatta EG Le Couteur D Shaw RJ Navas P Puigserver P Ingram DK de Cabo R Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Lagouge M Argmann C Gerhart-Hines Z Meziane H Lerin C Daussin F Messadeq N Milne J Lambert P Elliott P Geny B Laakso M Puigserver P Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell ; : — Barger JL Kayo T Vann JM Arias EB Wang J Hacker TA Wang Y Raederstorff D Morrow JD Leeuwenburgh C Allison DB Saupe KW Cartee GD Weindruch R Prolla TA. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One ; 3 : e Price NL Gomes AP Ling AJ Duarte FV Martin-Montalvo A North BJ Agarwal B Ye L Ramadori G Teodoro JS Hubbard BP Varela AT Davis JG Varamini B Hafner A Moaddel R Rolo AP Coppari R Palmeira CM de Cabo R Baur JA Sinclair DA. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab ; 15 : — Um JH Park SJ Kang H Yang S Foretz M McBurney MW Kim MK Viollet B Chung JH. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes ; 59 : — Park SJ Ahmad F Philp A Baar K Williams T Luo H Ke H Rehmann H Taussig R Brown AL Kim MK Beaven MA Burgin AB Manganiello V Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Dao TM Waget A Klopp P Serino M Vachoux C Pechere L Drucker DJ Champion S Barthelemy S Barra Y Burcelin R Seree E. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One ; 6 : e Elliot PJ Walpote SM Morelli L Lambert W Lunsmann W Westphal CH Lavu S. Drugs of the Future ; 34 : — Crandall JP Oram V Trandafirescu G Reid M Kishore P Hawkins M Cohen HW Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci ; 67 : — Bhatt JK Thomas S Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res ; 32 : — Brasnyo P Molnar GA Mohas M Marko L Laczy B Cseh J Mikolas E Szijarto IA Merei A Halmai R Meszaros LG Sumegi B Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr ; : — Tome-Carneiro J Larrosa M Yanez-Gascon MJ Davalos A Gil-Zamorano J Gonzalvez M Garcia-Almagro FJ Ruiz Ros JA Tomas-Barberan FA Espin JC Garcia-Conesa MT. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res ; 72 : 69 — Timmers S Konings E Bilet L Houtkooper RH van de Weijer T Goossens GH Hoeks J van der Krieken S Ryu D Kersten S Moonen-Kornips E Hesselink MK Kunz I Schrauwen-Hinderling VB Blaak EE Auwerx J Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab ; 14 : — Knop FK Konings E Timmers S Schrauwen P Holst JJ Blaak EE. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet Med Poulsen MM Vestergaard PF Clasen BF Radko Y Christensen LP Stodkilde-Jorgensen H Moller N Jessen N Pedersen SB Jorgensen JO. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes ; 62 : — Yoshino J Conte C Fontana L Mittendorfer B Imai S Schechtman KB Gu C Kunz I Rossi Fanelli F Patterson BW Klein S. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab ; 16 : — Ghanim H Sia CL Korzeniewski K Lohano T Abuaysheh S Marumganti A Chaudhuri A Dandona P. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab ; 96 : — Smoliga JM Colombo ES Campen MJ. A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations. Aging ; 5 : — Crandall JP Barzilai N. Exploring the promise of resveratrol: where do we go from here? Turrens JF Lariccia J Nair MG. Resveratrol has no effect on lipoprotein profile and does not prevent peroxidation of serum lipids in normal rats. Free Radic Res ; 27 : — Miller RA Harrison DE Astle CM Baur JA Boyd AR de Cabo R Fernandez E Flurkey K Javors MA Nelson JF Orihuela CJ Pletcher S Sharp ZD Sinclair D Starnes JW Wilkinson JE Nadon NL Strong R. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci ; 66 : — Fukao H Ijiri Y Miura M Hashimoto M Yamashita T Fukunaga C Oiwa K Kawai Y Suwa M Yamamoto J. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul Fibrinolysis ; 15 : — Wang Z Huang Y Zou J Cao K Xu Y Wu JM. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Kaneko H Anzai T Morisawa M Kohno T Nagai T Anzai A Takahashi T Shimoda M Sasaki A Maekawa Y Yoshimura K Aoki H Tsubota K Yoshikawa T Okada Y Ogawa S Fukuda K. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis ; : — Pace-Asciak CR Hahn S Diamandis EP Soleas G Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta ; : — Breen DM Dolinsky VW Zhang H Ghanim H Guo J Mroziewicz M Tsiani EL Bendeck MP Dandona P Dyck JR Heximer SP Giacca A. Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Behbahani J Thandapilly SJ Louis XL Huang Y Shao Z Kopilas MA Wojciechowski P Netticadan T Anderson HD. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens ; 23 : — Thandapilly SJ Wojciechowski P Behbahani J Louis XL Yu L Juric D Kopilas MA Anderson HD Netticadan T. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Rivera L Moron R Zarzuelo A Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol ; 77 : — Wallerath T Deckert G Ternes T Anderson H Li H Witte K Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation ; : — Kasdallah-Grissa A Mornagui B Aouani E Hammami M Gharbi N Kamoun A El-Fazaa S. Protective effect of resveratrol on ethanol-induced lipid peroxidation in rats. Alcohol Alcohol ; 41 : — Toklu HZ Sehirli O Ersahin M Suleymanoglu S Yiginer O Emekli-Alturfan E Yarat A Yegen BC Sener G. Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats. J Pharm Pharmacol ; 62 : — Wong RH Howe PR Buckley JD Coates AM Kunz I Berry NM. Nutr Metab Cardiovasc Dis ; 21 : — Wong RH Berry NM Coates AM Buckley JD Bryan J Kunz I Howe PR. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J Hypertens Magyar K Halmosi R Palfi A Feher G Czopf L Fulop A Battyany I Sumegi B Toth K Szabados E. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc ; 50 : — Lekakis J Rallidis LS Andreadou I Vamvakou G Kazantzoglou G Magiatis P Skaltsounis AL Kremastinos DT. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil ; 12 : — Kennedy DO Wightman EL Reay JL Lietz G Okello EJ Wilde A Haskell CF. Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. This content does not have an English version. This content does not have an Arabic version. Appointments at Mayo Clinic Mayo Clinic offers appointments in Arizona, Florida and Minnesota and at Mayo Clinic Health System locations. Request Appointment. Red wine and resveratrol: Good for your heart? Products and services. By Mayo Clinic Staff. Thank you for subscribing! Sorry something went wrong with your subscription Please, try again in a couple of minutes Retry. Show references Tangney CC, et al. Cardiovascular benefits and risks of moderate alcohol consumption. Accessed June 15, Mukamal KJ. Overview of the risks and benefits of alcohol consumption. Libby P, et al. Cardiomyopathies induced by drugs or toxins. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier; Rethinking drinking: Alcohol and your health. National Institute on Alcohol Abuse and Alcoholism. Department of Health and Human Services and U. Department of Agriculture. Scientific Report of the Dietary Guidelines Advisory Committee. Alcoholic beverages. Is drinking alcohol part of a healthy lifestyle? American Heart Association. Drinking red wine for heart health? Read this before you toast. Krittanawong C, et al. Alcohol consumption and cardiovascular health. The American Journal of Medicine. Lopez-Jimenez F expert opinion. Mayo Clinic. June 20, Products and Services Blood Pressure Monitors at Mayo Clinic Store A Book: Live Younger Longer A Book: Future Care. See also Angina Atkins Diet Automated external defibrillators: Do you need an AED? Blood Basics Blood tests for heart disease Bradycardia Transplant advances Butter vs. margarine Calcium supplements: A risk factor for heart attack? Can vitamins help prevent a heart attack? Cardiac ablation Cardiac amyloidosis — Treatment options Cardiac amyloidosis — What is amyloid and how does it affect the heart Cardiac catheterization Cardioversion Chelation therapy for heart disease: Does it work? Chest X-rays Complete blood count CBC Coronary angiogram Coronary angioplasty and stents Coronary artery bypass surgery Coronary artery spasm: Cause for concern? Cough CT scan Daily aspirin therapy Dizziness Don't get tricked by these 3 heart-health myths Echocardiogram Ejection fraction: What does it measure? Electrocardiogram ECG or EKG Heart transplant to treat dilated cardiomyopathy: Elmo's story Erectile dysfunction: A sign of heart disease? Exercise and chronic disease Fasting diet: Can it improve my heart health? Fatigue Flu Shot Prevents Heart Attack Flu shots and heart disease Grass-fed beef Healthy Heart for Life!
Resveratrol May Play Key Role in Lowering High Blood Pressure	Breen DM Sanli T Giacca A Tsiani E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun ; : — Sun C Zhang F Ge X Yan T Chen X Shi X Zhai Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab ; 6 : — Chen WP Chi TC Chuang LM Su MJ. Resveratrol enhances insulin secretion by blocking K ATP and K V channels of beta cells. Eur J Pharmacol ; : — Baur JA Pearson KJ Price NL Jamieson HA Lerin C Kalra A Prabhu VV Allard JS Lopez-Lluch G Lewis K Pistell PJ Poosala S Becker KG Boss O Gwinn D Wang M Ramaswamy S Fishbein KW Spencer RG Lakatta EG Le Couteur D Shaw RJ Navas P Puigserver P Ingram DK de Cabo R Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Lagouge M Argmann C Gerhart-Hines Z Meziane H Lerin C Daussin F Messadeq N Milne J Lambert P Elliott P Geny B Laakso M Puigserver P Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell ; : — Barger JL Kayo T Vann JM Arias EB Wang J Hacker TA Wang Y Raederstorff D Morrow JD Leeuwenburgh C Allison DB Saupe KW Cartee GD Weindruch R Prolla TA. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One ; 3 : e Price NL Gomes AP Ling AJ Duarte FV Martin-Montalvo A North BJ Agarwal B Ye L Ramadori G Teodoro JS Hubbard BP Varela AT Davis JG Varamini B Hafner A Moaddel R Rolo AP Coppari R Palmeira CM de Cabo R Baur JA Sinclair DA. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab ; 15 : — Um JH Park SJ Kang H Yang S Foretz M McBurney MW Kim MK Viollet B Chung JH. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes ; 59 : — Park SJ Ahmad F Philp A Baar K Williams T Luo H Ke H Rehmann H Taussig R Brown AL Kim MK Beaven MA Burgin AB Manganiello V Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Dao TM Waget A Klopp P Serino M Vachoux C Pechere L Drucker DJ Champion S Barthelemy S Barra Y Burcelin R Seree E. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One ; 6 : e Elliot PJ Walpote SM Morelli L Lambert W Lunsmann W Westphal CH Lavu S. Drugs of the Future ; 34 : — Crandall JP Oram V Trandafirescu G Reid M Kishore P Hawkins M Cohen HW Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci ; 67 : — Bhatt JK Thomas S Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res ; 32 : — Brasnyo P Molnar GA Mohas M Marko L Laczy B Cseh J Mikolas E Szijarto IA Merei A Halmai R Meszaros LG Sumegi B Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr ; : — Tome-Carneiro J Larrosa M Yanez-Gascon MJ Davalos A Gil-Zamorano J Gonzalvez M Garcia-Almagro FJ Ruiz Ros JA Tomas-Barberan FA Espin JC Garcia-Conesa MT. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res ; 72 : 69 — Timmers S Konings E Bilet L Houtkooper RH van de Weijer T Goossens GH Hoeks J van der Krieken S Ryu D Kersten S Moonen-Kornips E Hesselink MK Kunz I Schrauwen-Hinderling VB Blaak EE Auwerx J Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab ; 14 : — Knop FK Konings E Timmers S Schrauwen P Holst JJ Blaak EE. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet Med Poulsen MM Vestergaard PF Clasen BF Radko Y Christensen LP Stodkilde-Jorgensen H Moller N Jessen N Pedersen SB Jorgensen JO. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes ; 62 : — Yoshino J Conte C Fontana L Mittendorfer B Imai S Schechtman KB Gu C Kunz I Rossi Fanelli F Patterson BW Klein S. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab ; 16 : — Ghanim H Sia CL Korzeniewski K Lohano T Abuaysheh S Marumganti A Chaudhuri A Dandona P. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab ; 96 : — Smoliga JM Colombo ES Campen MJ. A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations. Aging ; 5 : — Crandall JP Barzilai N. Exploring the promise of resveratrol: where do we go from here? Turrens JF Lariccia J Nair MG. Resveratrol has no effect on lipoprotein profile and does not prevent peroxidation of serum lipids in normal rats. Free Radic Res ; 27 : — Miller RA Harrison DE Astle CM Baur JA Boyd AR de Cabo R Fernandez E Flurkey K Javors MA Nelson JF Orihuela CJ Pletcher S Sharp ZD Sinclair D Starnes JW Wilkinson JE Nadon NL Strong R. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci ; 66 : — Fukao H Ijiri Y Miura M Hashimoto M Yamashita T Fukunaga C Oiwa K Kawai Y Suwa M Yamamoto J. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul Fibrinolysis ; 15 : — Wang Z Huang Y Zou J Cao K Xu Y Wu JM. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Kaneko H Anzai T Morisawa M Kohno T Nagai T Anzai A Takahashi T Shimoda M Sasaki A Maekawa Y Yoshimura K Aoki H Tsubota K Yoshikawa T Okada Y Ogawa S Fukuda K. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis ; : — Pace-Asciak CR Hahn S Diamandis EP Soleas G Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta ; : — Breen DM Dolinsky VW Zhang H Ghanim H Guo J Mroziewicz M Tsiani EL Bendeck MP Dandona P Dyck JR Heximer SP Giacca A. Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Behbahani J Thandapilly SJ Louis XL Huang Y Shao Z Kopilas MA Wojciechowski P Netticadan T Anderson HD. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am J Hypertens ; 23 : — Thandapilly SJ Wojciechowski P Behbahani J Louis XL Yu L Juric D Kopilas MA Anderson HD Netticadan T. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Rivera L Moron R Zarzuelo A Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol ; 77 : — Wallerath T Deckert G Ternes T Anderson H Li H Witte K Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation ; : — Kasdallah-Grissa A Mornagui B Aouani E Hammami M Gharbi N Kamoun A El-Fazaa S. Protective effect of resveratrol on ethanol-induced lipid peroxidation in rats. Alcohol Alcohol ; 41 : — Toklu HZ Sehirli O Ersahin M Suleymanoglu S Yiginer O Emekli-Alturfan E Yarat A Yegen BC Sener G. Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats. J Pharm Pharmacol ; 62 : — Wong RH Howe PR Buckley JD Coates AM Kunz I Berry NM. Nutr Metab Cardiovasc Dis ; 21 : — Wong RH Berry NM Coates AM Buckley JD Bryan J Kunz I Howe PR. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J Hypertens Magyar K Halmosi R Palfi A Feher G Czopf L Fulop A Battyany I Sumegi B Toth K Szabados E. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc ; 50 : — Lekakis J Rallidis LS Andreadou I Vamvakou G Kazantzoglou G Magiatis P Skaltsounis AL Kremastinos DT. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil ; 12 : — Kennedy DO Wightman EL Reay JL Lietz G Okello EJ Wilde A Haskell CF. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr ; 91 : — Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol ; 49 : — Yashiro T Nanmoku M Shimizu M Inoue J Sato R. Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element-binding proteins. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem Toxicol ; 52 : 12 — Zang M Xu S Maitland-Toolan KA Zuccollo A Hou X Jiang B Wierzbicki M Verbeuren TJ Cohen RA. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes ; 55 : — Tome-Carneiro J Gonzalvez M Larrosa M Garcia-Almagro FJ Aviles-Plaza F Parra S Yanez-Gascon MJ Ruiz-Ros JA Garcia-Conesa MT Tomas-Barberan FA Espin JC. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res ; 56 : — Ghanim H Sia CL Abuaysheh S Korzeniewski K Patnaik P Marumganti A Chaudhuri A Dandona P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab ; 95 : E1 — 8. Gresele P Pignatelli P Guglielmini G Carnevale R Mezzasoma AM Ghiselli A Momi S Violi F. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr ; : — Wang Z Zou J Huang Y Cao K Xu Y Wu JM. Effect of resveratrol on platelet aggregation in vivo and in vitro. Two review authors independently extracted data on study characteristics, methods and outcomes. Overall, the impact of resveratrol on BP was reported in 17 trials. Results: Administration of resveratrol did not significantly affect neither systolic BP [weighted mean difference WMD : Meta-regression analysis revealed a positive association between systolic BP-lowering resveratrol activity slope: 1. You Might Also Like News. Tim Fish. Suzanne Mustacich. Aaron Romano Collin Dreizen. Tom Kline. Julia Larson. Shayna Condé. Explore Newsletters. Restaurant Search. Wine Spectator Podcasts Get the App.

Resveratrol and blood pressure -

In light of these promising clinical findings and previously reported preclinical evidence, resveratrol appears to be a potential antihypertensive agent.

The efficacy of resveratrol has yet to be clinically investigated in patients with hypertension. This trial will be the first study to investigate the potential of therapeutic use of resveratrol for the management of BP in patients diagnosed with prehypertension and type 1 hypertension.

The outcomes from this study will help to determine the efficacy of short-term resveratrol treatment in hypertensive patients and bridge the gap with regards to the current preclinical and clinical evidence.

This study will also help in collecting further information with regard to identifying a therapeutically effective dose of resveratrol in controlling cardiovascular disease risk factors. Importantly, if a positive outcome is identified, it will provide us with an effective therapeutic strategy to combat hypertension and would pave the way for achieving enormous public health benefit.

This trial is designed as a pilot study to investigate the efficacy of resveratrol as a blood-pressure-lowering agent in a specific population.

In addition, the trial has a small sample size. Hypertension is a condition that requires long-term medication. Because the trial duration is only 4 weeks, longer-term studies need to be conducted to evaluate the efficacy of resveratrol as a sustained treatment option.

In this study, participants will receive daily only a single, high dose of resveratrol, which will be taken twice throughout the study a high dose that is well tolerated.

Further trials may be needed to ascertain whether resveratrol can lower BP at a much lower daily dose. Another limitation is that a pharmacokinetics study will not be done in this trial to understand the absorption, distribution, metabolism, and excretion of resveratrol in hypertensive patients; pharmacokinetics may have helped to draw a correlation between the plasma bioavailability and the actual physiological effect.

In this trial, stage 1-hypertensive patients will be on standard therapy for hypertension as well; therefore, it may not be possible to understand the standalone efficacy of resveratrol in lowering BP in these patients. Extensive toxicological analysis will also not be conducted as part of this study.

ALP, alkaline phosphatase; Ang, angiotensin; BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; DSMB, Data and Safety Monitoring Board; GGT, gamma-glutamyl transferase; HCT, hematocrit; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LFT, liver function test; NO, nitric oxide; PLT, platelet; PT, prothrombin time; PTT, partial thromboplastin time; RLT, renal function test; SHR, spontaneously hypertensive rat; TG, triglyceride; TNF-α, tumor necrosis factor- α.

Eurosurveillance editorial team. Who launches the world health statistics ? Euro Surveill. Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association.

Article CAS PubMed Google Scholar. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment.

A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Swain JF, McCarron PB, Hamilton EF, Sacks FM, Appel LJ.

Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease omniheart : options for a heart-healthy diet. J Am Diet Assoc. Article CAS PubMed PubMed Central Google Scholar.

Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. Article PubMed Google Scholar.

Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Raj P, Louis XL, Thandapilly SJ, Movahed A, Zieroth S, Netticadan T. Potential of resveratrol in the treatment of heart failure. Life Sci.

Thandapilly SJ, Louis XL, Behbahani J, Movahed A, Yu L, Fandrich R, et al. Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats. Hypertens Res. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, et al.

Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Chun C, Yang W, Xueding C, Qi Z, Xiaoying H, Honglei X, et al.

Resveratrol downregulates acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 mitogen-activated protein kinase and monocyte chemoattractant protein-1 signaling in rats.

Mattison JA, Wang M, Bernier M, Zhang J, Park SS, Maudsley S, et al. Cell Metab. Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients.

PubMed PubMed Central Google Scholar. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. Raper NPB, Ingwersen L, Steinfeldt L, Jaswinder A. J Food Comp Anal. Article Google Scholar.

Ashwood CABaER. Tietz textbook of clinical chemistry. Philadelphia: W. B Saunders; Google Scholar. Friedewald WT, Levy RI, Fredrickson DS.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Clin Chem. CAS PubMed Google Scholar. Kim Y, Park I, Kang M. Convergent validity of the international physical activity questionnaire ipaq : meta-analysis. Public Health Nutr.

Download references. This work was supported by a grant from Research Deputy of Bushehr University of Medical Sciences, Iran. We also thank Biotivia Longevity Bioceuticals LLC Company, USA, for supplying us with resveratrol and its placebo.

AM is the principal investigator of the study; he will be primarily responsible for conducting the clinical trial, getting the human ethics approvals, and the collection and storage of clinical trial samples and confidential data.

TN and AM originated the concept for this human trial. AO, AM, XLL, SJT, PR, JMS, and TN were involved in the planning and designing the study. AM and AO were involved in the preparation of the study protocol. AM and DI will be responsible for the recruitment and data collection. AO will analyze all the data from the study.

XLL, SJT, PR, JS, and TN have contributed to writing and editing the trial manuscript. All authors have read and approved the final manuscript.

The Persian Gulf Tropical Medicine Research Center, Biochemistry Group, Bushehr University of Medical Sciences, Bushehr, Iran. Canadian Centre for Agri-Food Research in Health and Medicine, Winnipeg, R2H 2A6, Canada. Department of Cardiology, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran.

Agriculture and Agri-Food Canada, Winnipeg, Manitoba, R3T 2M9, Canada. Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Manitoba, R3E 0J9, Canada. Department of Physical Therapy, High Point University, High Point, NC, , USA.

Department of Basic Pharmaceutical Sciences, High Point University, High Point, NC, , USA. Heart Failure Research Laboratory, Canadian Centre for Agri-Food Research in Health and Medicine, R, St. Boniface Research Centre, Tache Avenue, Winnipeg, Manitoba, R2H 2A6, Canada. You can also search for this author in PubMed Google Scholar.

Correspondence to Ali Movahed or Thomas Netticadan. The patients will be informed that they are participating in a clinical trial that assesses the effectiveness of oral resveratrol in prehypertension and stage 1 hypertension.

Previous studies have shown that the drug does not have serious adverse effects at levels prescribed in this study and has had favorable effects on the manifestations of the disease. This clinical trial will be done on 50 patients with prehypertension diastolic BP and systolic BP, 80—89 mmHg and — mmHg, respectively and 50 patients with stage 1 hypertension diastolic and systolic, 90—99 mmHg and — mmHg, respectively in the School of Medicine of Bushehr University of Medical Sciences in Iran.

Participants do not have to make a prompt decision, and they can consult anybody they want before making their final decision. All the participants should enter and stay in the study voluntarily, and with full knowledge of the situation.

It often mimics antioxidant activity in the body and may provide many health benefits. Research most supports its use for cardiovascular protection and blood pressure regulation. People may consume resveratrol through foods or supplements. There is no conclusive recommended dosage for resveratrol, but consuming large amounts may lead to gastrointestinal upset.

A doctor, dietitian, or other qualified health professional may be helpful in determining the appropriate amount of resveratrol for an individual. People have cultivated grapes for 8, years. Grapes come in a range of colors and types, have been turned into jams and jellies, and made into wine….

Antioxidants are in many healthful foods. Experts believe that they help the body fight harmful free radicals that can lead to various health…. Blueberries are considered a superfood, and can help maintain healthy bones, reduce blood pressure, manage diabetes, and ward off heart disease.

Free radicals are unstable atoms that can cause damage to cells and lead to illnesses and the aging process. Exactly what impact do they have on the…. This article identifies the 15 most healthful foods based on recent research.

The list includes nuts, berries, fish, and eggs, all of which a person…. My podcast changed me Can 'biological race' explain disparities in health? Why Parkinson's research is zooming in on the gut Tools General Health Drugs A-Z Health Hubs Health Tools Find a Doctor BMI Calculators and Charts Blood Pressure Chart: Ranges and Guide Breast Cancer: Self-Examination Guide Sleep Calculator Quizzes RA Myths vs Facts Type 2 Diabetes: Managing Blood Sugar Ankylosing Spondylitis Pain: Fact or Fiction Connect About Medical News Today Who We Are Our Editorial Process Content Integrity Conscious Language Newsletters Sign Up Follow Us.

Medical News Today. Health Conditions Health Products Discover Tools Connect. What to know about resveratrol. Medically reviewed by Katherine Marengo LDN, R. What it is Benefits Side effects How to consume Dosage Summary Resveratrol is a plant compound derived from red grapes that has antioxidant-like properties.

What is resveratrol? Side effects and risks. How to consume. How we reviewed this article: Sources. Medical News Today has strict sourcing guidelines and draws only from peer-reviewed studies, academic research institutions, and medical journals and associations. We avoid using tertiary references.

We link primary sources — including studies, scientific references, and statistics — within each article and also list them in the resources section at the bottom of our articles. Sorry something went wrong with your subscription Please, try again in a couple of minutes Retry.

Show references Tangney CC, et al. Cardiovascular benefits and risks of moderate alcohol consumption. Accessed June 15, Mukamal KJ. Overview of the risks and benefits of alcohol consumption.

Libby P, et al. Cardiomyopathies induced by drugs or toxins. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier; Rethinking drinking: Alcohol and your health. National Institute on Alcohol Abuse and Alcoholism. Department of Health and Human Services and U.

Department of Agriculture. Scientific Report of the Dietary Guidelines Advisory Committee. Alcoholic beverages. Is drinking alcohol part of a healthy lifestyle? American Heart Association.

Drinking red wine for heart health? Read this before you toast. Krittanawong C, et al. Alcohol consumption and cardiovascular health. The American Journal of Medicine.

Lopez-Jimenez F expert opinion. Mayo Clinic. June 20, Products and Services Blood Pressure Monitors at Mayo Clinic Store A Book: Live Younger Longer A Book: Future Care. See also Angina Atkins Diet Automated external defibrillators: Do you need an AED?

Blood Basics Blood tests for heart disease Bradycardia Transplant advances Butter vs. margarine Calcium supplements: A risk factor for heart attack? Can vitamins help prevent a heart attack? Cardiac ablation Cardiac amyloidosis — Treatment options Cardiac amyloidosis — What is amyloid and how does it affect the heart Cardiac catheterization Cardioversion Chelation therapy for heart disease: Does it work?

Chest X-rays Complete blood count CBC Coronary angiogram Coronary angioplasty and stents Coronary artery bypass surgery Coronary artery spasm: Cause for concern? Cough CT scan Daily aspirin therapy Dizziness Don't get tricked by these 3 heart-health myths Echocardiogram Ejection fraction: What does it measure?

Electrocardiogram ECG or EKG Heart transplant to treat dilated cardiomyopathy: Elmo's story Erectile dysfunction: A sign of heart disease? Exercise and chronic disease Fasting diet: Can it improve my heart health?

Fatigue Flu Shot Prevents Heart Attack Flu shots and heart disease Grass-fed beef Healthy Heart for Life! Heart arrhythmia Heart attack Heart attack prevention: Should I avoid secondhand smoke?

Heart attack symptoms Heart Attack Timing Heart disease Heart disease in women: Understand symptoms and risk factors Heart-healthy diet: 8 steps to prevent heart disease Heart murmurs Heart transplant Herbal supplements and heart drugs Holter monitor Honey: An effective cough remedy?

Implantable cardioverter-defibrillators ICDs Leg swelling Mediterranean diet Menus for heart-healthy eating NSAIDs: Do they increase my risk of heart attack and stroke?

Nuclear stress test Numbness Nuts and your heart: Eating nuts for heart health Omega-3 in fish Omega-6 fatty acids Organ transplant in highly sensitized patients Pacemaker Pericardial effusion Polypill: Does it treat heart disease?

Pseudoaneurysm: What causes it? Pulmonary edema Shortness of breath Silent heart attack Sitting risks: How harmful is too much sitting? Heart disease prevention Stress symptoms Stress test Tachycardia The Last Brother's Heart Integrative approaches to treating pain Nutrition and pain Pain rehabilitation Self-care approaches to treating pain Trans fat Triathlete transplant Coronary angioplasty Video: Heart and circulatory system What is meant by the term "heart age"?

Show more related content. Mayo Clinic Press Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press. Mayo Clinic on Incontinence - Mayo Clinic Press Mayo Clinic on Incontinence The Essential Diabetes Book - Mayo Clinic Press The Essential Diabetes Book Mayo Clinic on Hearing and Balance - Mayo Clinic Press Mayo Clinic on Hearing and Balance FREE Mayo Clinic Diet Assessment - Mayo Clinic Press FREE Mayo Clinic Diet Assessment Mayo Clinic Health Letter - FREE book - Mayo Clinic Press Mayo Clinic Health Letter - FREE book.

Rena M. Pollack, Jill Resveragrol. Resveratrol and blood pressure, a natural polyphenol, has gained attention in pressyre years because of its pressurf with the Rezveratrol Resveratrol and blood pressure of red Pumpkin Seed Harvesting and its anticancer activity in vitro. Studies in animal models have demonstrated beneficial effects on glucose metabolism, vascular function and anti-inflammatory and antioxidant properties. Human studies designed to understand the role of resveratrol in the prevention and treatment of age-related conditions such as diabetes, heart disease, and cancer have recently been undertaken.